Skip to content

Clinical Safety & Pharmacovigilance

Clinical Safety Services >

Postmarketed Pharmacovigilance Services >

Innovation & Technology >

Clinical SAE Processing & Expedited Reporting

Investigator Brochures Authoring and Updating

Medical Review of SAE

Global and Local Medical Literature Monitoring

Medical Monitoring

Signal Detection & Signal Management

Development Safety Update Report (DSUR) Authoring

Reconciliation with Partners, Clinical Database

Responsible Person for Pharmacovigilance (RPPV)

CSR Narratives Authoring

Pharmacovigilance SOPs and Safety System Setup & Maintenance, PSMF, Audits & Inspections

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025

Case Intake, Processing, Submissions, & Medical Review

Aggregate Reports – PSUR, PBRER, ASR, PADER, Report Calendar Management & Submission

Risk Management Plan (RMP), Risk Minimization & REMs

Global and Local Medical Literature Monitoring

Responsible Person for Pharmacovigilance (RPPV), Qualified Person for Pharmacovigilance & Global Local Safety Support

Pharmacovigilance SOPs and Safety System Setup & Maintenance, PSMF, Audits & Inspections

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025

Hosted Drug Safety Database – ArisGlobal LSMV™, LSRA™, ARGUS™ & Veeva Safety™

Global & Local Literature Management Platform – UNITY™ai.Lit

Integrated MICC Platform – Medical Information, Product Complaints & AE Processing

Collaborative Medical Writing with Generative AI Support Platform- UNITY™dx

Safety Case Intake & Case Processing Platform – AnyForm, AnyLanguage & AnySystem

Managed Services, Hosting & Reporting for Drug Safety

Pharmacovigilance Partners Agreements (PVA, SDEA) Management and Case Exchange – UNITY™dx

Validation and CSV Support

Clinical Documents Exchange Platform – UNITY™dx

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025
Medical Affairs and Medical Writing

Medical Affairs and Medical Writing >

Innovation & Technology >

Multilingual Global Medical Information Call Center

Developing & Managing FAQs and Standard Response Letters

Developing Core Slide Decks

Systematic Literature Review

Posters and Abstracts

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025

Collaborative Medical Writing with Generative AI Support Platform- UNITY™dx

Integrated MICC Platform – Medical Information, Product Complaints & AE Processing

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025
Insights

Blogs >

White Papers >

News >

Case Studies >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Postmarketing Adverse Drug Experience (PADE) Inspections – Part II

Postmarketing Adverse Drug Experience (PADE) Inspections – Part I

Audits in Pharmacovigilance: A commitment to Safety

See More

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025

Reference Safety Information in Clinical Trials

See More

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025

Soterius appoints Dr. Sumit Verma, MD, DNB to lead operations

Soterius : What does it mean ? When did it begin ?

Soterius appoints its first CEO

Soterius will attend World Drug Safety Congress – Europe

Soterius Expands US Operations

See More

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025

Streamlining Regulatory Compliance in Multisite Clinical Trials through Automation

Global Literature Surveillance Project

Handling Unexpected High Call Volumes

See More

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025
Events

Upcoming Meetings & Webinars >

Past Meetings & Webinars >

World Drug Safety Congress, Europe 2025

World Drug Safety Congress, Americas 2025

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025

Soterius at German Pharmacovigilance Day 2025

Drug Information and Association Conference, Congress Centre Basel, Switzerland

Drug Information and Association Conference, Hilton Baltimore Inner Harbor, Baltimore, USA

World Drug Safety Congress- Americas, Boston Convention and Exhibition Centre, Boston, MA

World Drug Safety Congress- Europe, RAI- Amsterdam

World Drug Safety Congress – Americas, Boston, Massachusetts, USA

World Drug Safety Congress, Amsterdam, Europe

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025
About Us

About Us >

Our Global Experts

Contact Us

Careers

Resources >

Postmarketing Adverse Drug Experience (PADE) Inspections – Part IV

Post marketing Adverse Drug Experience (PADE) Inspections – Part III

Events >

World Drug Safety Congress, Europe 2025